Glanbia Plc · EURONEXT:GL9
Glanbia — Q1 2026 Earnings Presentation
10 slides from Glanbia's earnings presentation, Apr 29, 2026
Slide 1: Q1 2026 Interim Management Statement
Q1 2026 Interim Management Statement 29 April 2026 Hugh McGuire Mark Garvey Chief Executive Officer Chief Financial Officer
Slide 2: Important Notice
I M P O R T A N T N O T I C E This presentation contains forward-looking statements. These statements have been made by the Directors in good faith based on the information available to them up to the time of their approval of this presentation. Due to the inherent uncertainties, including both econ
Slide 3: Highlights
HIGHLIGHTS Q1 2026 Strong YTD Q1 performance with volume growth and continued positive momentum across all three segments Optimum Nutrition delivered +18.8% LFL revenue growth1 driven by accelerating category growth, expanded distribution and innovation Strong volume growth of +12.5% in H&N driven b
Slide 4: Performance Nutrition (PN)
PERFORMANCE NUTRITION (PN) Strong first quarter performance led by Optimum Nutrition Total revenue Q1 YTD1 +1.3% Volume +9.2% Price +2.3% Disposals (10.2%) • LFL revenue2 +11.5% • Volume +9.2% driven by accelerating category growth, new distribution, lapping of weaker comparative and innovation • Pr
Slide 5: Health & Nutrition (H&N)
H E A LT H & N U T R I T I O N ( H & N ) Continued strong volume growth momentum driven by demand in end-use markets Total revenue Q1 YTD1 +14.8% Volume +12.5% Price (0.9%) Acquisitions +3.2% • H&N LFL2 revenue growth of +11.6% • Volume +12.5% driven by strong demand across priority end-use markets
Slide 6: Dairy Nutrition (DN)
D A I RY N U T R I T I O N ( D N ) Strong performance through volume and pricing in Protein Solutions Total revenue Q1 YTD1 +2.0% Volume +6.4% Price (4.4%) • LFL2 revenue growth of +2.0% • Volume +6.4% driven by continued strong demand for protein solutions and bioactives with demand for high-end wh
Slide 7: Strong Balance Sheet
STRONG BALANCE SHEET DEBT CAPITAL SHAREHOLDER EXPENDITURE RETURNS Net Debt $648m FY26 capex expected to be €100m share buyback $100m – $110m authorisation Total committed facilities of $1.4bn €22.2m returned via share buyback programme1 to date Final dividend 25.67 €cent 7 | Glanbia PLC Q1 2026 IMS
Slide 8: FY26 Outlook Aligned with Medium-Term Growth Algorithm
FY26 OUTLOOK ALIGNED WITH MEDIUM -TERM GROWTH ALGORITHM PN H&N DN Revenue growth: upper end of +5-7% Revenue growth: upper end of +4-6% EBITDA in the range of EBITDA margin progression EBITDA margin: 17-19% $160-170m (above medium- term guidance) Adj. EPS1 at upper end of 7% - 11% OCF Conversion 85%
Slide 9: Delivering Better Nutrition
DELIVERING BETTER NUTRITION 1 High-growth categories with leading brands and ingredients driven by consumer megatrends 2 Sharpened and focused operating model and portfolio to capture the growth 3 Our people, portfolio, and firepower will continue to drive strong shareholder returns 9 | Glanbia PLC
Slide 10: A Performance Driven Purpose Led Global Nutrition Company
A PERFORMANCE DRIVEN PURPOSE L E D G L O B A L N U T R I T I O N C O M PA N Y 10 | Glanbia PLC Q1 2026 IMS Presentation